Cost–Benefit Analysis in Health Care: the Case of Bariatric Surgery Compared With Diet

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F20%3A00337416" target="_blank" >RIV/68407700:21460/20:00337416 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1016/j.clinthera.2019.12.001" target="_blank" >https://doi.org/10.1016/j.clinthera.2019.12.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clinthera.2019.12.001" target="_blank" >10.1016/j.clinthera.2019.12.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cost–Benefit Analysis in Health Care: the Case of Bariatric Surgery Compared With Diet

Popis výsledku v původním jazyce

The aim of the present study was to assess, by using a cost–benefit analysis, the net monetary benefit (NMB) of bariatric surgery compared with diet (including physical exercise) for obese patients, from both an Italian payer perspective and the broader societal perspective. The study considered the following groups of patients: (1) patients with a body mass index (BMI) >=40 kg/m2 without complications + patients with BMI >=35 kg/m2 with complications; (2) patients with BMI >=35 kg/m2 and diabetes; and (3) patients with BMI ranging from 30 to 35 kg/m2 and diabetes. A Markov model was developed to project the lifetime health outcomes (life years and quality-adjusted life years [QALYs]) and costs associated with bariatric surgery and diet for the considered groups of patients. The clinical effectiveness of each strategy was based on the likelihood of experiencing cardiovascular events or events related to the presence of diabetes. Data on clinical effectiveness, quality of life, productivity losses, and out-of-pocket costs were mainly derived from the literature; direct costs were obtained from official tariffs or the literature. Different scenarios were considered for the analyses in addition to the base case. According to both perspectives considered, the NMB was calculated by first assuming a willingness-to-pay threshold (30,000 per QALY), then converting health benefits (QALYs) into the common monetary metric (ie, the euro). NMB was calculated as follows: (incremental benefit x willingness-to-pay – incremental cost).

Název v anglickém jazyce

Cost–Benefit Analysis in Health Care: the Case of Bariatric Surgery Compared With Diet

Popis výsledku anglicky

The aim of the present study was to assess, by using a cost–benefit analysis, the net monetary benefit (NMB) of bariatric surgery compared with diet (including physical exercise) for obese patients, from both an Italian payer perspective and the broader societal perspective. The study considered the following groups of patients: (1) patients with a body mass index (BMI) >=40 kg/m2 without complications + patients with BMI >=35 kg/m2 with complications; (2) patients with BMI >=35 kg/m2 and diabetes; and (3) patients with BMI ranging from 30 to 35 kg/m2 and diabetes. A Markov model was developed to project the lifetime health outcomes (life years and quality-adjusted life years [QALYs]) and costs associated with bariatric surgery and diet for the considered groups of patients. The clinical effectiveness of each strategy was based on the likelihood of experiencing cardiovascular events or events related to the presence of diabetes. Data on clinical effectiveness, quality of life, productivity losses, and out-of-pocket costs were mainly derived from the literature; direct costs were obtained from official tariffs or the literature. Different scenarios were considered for the analyses in addition to the base case. According to both perspectives considered, the NMB was calculated by first assuming a willingness-to-pay threshold (30,000 per QALY), then converting health benefits (QALYs) into the common monetary metric (ie, the euro). NMB was calculated as follows: (incremental benefit x willingness-to-pay – incremental cost).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Therapeutics

ISSN

0149-2918

e-ISSN

1879-114X

Svazek periodika

42

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

23

Strana od-do

"60"-"75.e7"

Kód UT WoS článku

000516654800008

EID výsledku v databázi Scopus

2-s2.0-85078022563